ATAI
significant burden urgent need for innovation global population with mental health disorders of patients with depression respond inadequately or relapse us adults experiencing symptoms of depression and anxiety quadrupled treatments for depression and anxiety have slow onset depression is the leading cause of disability of patients treated for use disorder relapse economic burden from adults with major depressive disorder only new compounds approved by for depression since although has become one challenges there has been little | ATAI
Company
Deck date
October 2022
Slide
5 of 41
Related slides by other companies
Investor Day
January 2023
Investor Day
June 2023
Investor Presentation
June 2023
SPAC
April 2021
Other recent decks by ATAI
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io